# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHAPTER 1</strong></td>
<td></td>
</tr>
<tr>
<td>1 Introduction</td>
<td>1</td>
</tr>
<tr>
<td>1.1 Introduction: analytical chemistry</td>
<td>1</td>
</tr>
<tr>
<td>1.2 Analytical methods</td>
<td>2</td>
</tr>
<tr>
<td>1.3 General classification of analytical methods</td>
<td>3</td>
</tr>
<tr>
<td>1.3.1 Classical methods</td>
<td>3</td>
</tr>
<tr>
<td>1.3.2 Instrumental methods</td>
<td>3</td>
</tr>
<tr>
<td>1.3.3 Types of instrumental methods of analysis</td>
<td>4</td>
</tr>
<tr>
<td>1.3.4 Ultraviolet-visible absorption spectrophotometry</td>
<td>7</td>
</tr>
<tr>
<td>1.3.5 Spectrophotometric multi-component analysis</td>
<td>8</td>
</tr>
<tr>
<td>1.3.5.1 Simultaneous equation method (Vierodt’s method)</td>
<td>9</td>
</tr>
<tr>
<td>1.3.5.2 Absorbance ratio method</td>
<td>9</td>
</tr>
<tr>
<td>1.3.5.3 Derivative spectrophotometry</td>
<td>10</td>
</tr>
<tr>
<td>1.3.6 Chromatography</td>
<td>11</td>
</tr>
<tr>
<td>1.3.6.1 High performance thin layer chromatography</td>
<td>12</td>
</tr>
<tr>
<td>1.3.6.1.1 Principle</td>
<td>12</td>
</tr>
<tr>
<td>1.3.6.1.2 Steps of HPTLC separation</td>
<td>12</td>
</tr>
<tr>
<td>1.3.6.1.3 Selection of HPTLC plates and sorbents for the technique</td>
<td>13</td>
</tr>
<tr>
<td>1.3.6.1.4 Pretreatments of the TLC plate</td>
<td>13</td>
</tr>
<tr>
<td>1.3.6.1.5 Sample preparation technique</td>
<td>13</td>
</tr>
<tr>
<td>1.3.6.1.6 Application of sample on pre-coated plates</td>
<td>13</td>
</tr>
<tr>
<td>1.3.6.1.7 Optimization of mobile phase</td>
<td>13</td>
</tr>
<tr>
<td>1.3.6.1.8 Chamber saturation</td>
<td>14</td>
</tr>
<tr>
<td>1.3.6.1.9 Chromatographic development and drying</td>
<td>14</td>
</tr>
<tr>
<td>1.3.6.1.10 Detection and visualization</td>
<td>14</td>
</tr>
<tr>
<td>1.3.6.1.11 Quantification</td>
<td>14</td>
</tr>
<tr>
<td>1.3.6.1.12 Advantages of HPTLC</td>
<td>14</td>
</tr>
<tr>
<td>1.3.6.2 High performance liquid chromatography</td>
<td>16</td>
</tr>
<tr>
<td>1.3.6.2.1 UV detector</td>
<td>18</td>
</tr>
<tr>
<td>1.3.6.2.2 PDA detector</td>
<td>18</td>
</tr>
<tr>
<td>1.3.7 Development and validation of analytical methods</td>
<td>19</td>
</tr>
<tr>
<td>1.3.8 Method validation parameters</td>
<td>19</td>
</tr>
<tr>
<td>1.3.8.1 Accuracy</td>
<td>19</td>
</tr>
<tr>
<td>1.3.8.2 Precision</td>
<td>19</td>
</tr>
<tr>
<td>1.3.8.3 Linearity and range</td>
<td>20</td>
</tr>
<tr>
<td>1.3.8.4 Limit of detection and limit of quantification</td>
<td>20</td>
</tr>
<tr>
<td>1.3.8.5 Specificity</td>
<td>20</td>
</tr>
<tr>
<td>1.3.8.6 Robustness</td>
<td>20</td>
</tr>
<tr>
<td>1.3.8.7 System suitability parameters</td>
<td>20</td>
</tr>
<tr>
<td><strong>CHAPTER 2</strong></td>
<td>23</td>
</tr>
<tr>
<td><strong>CHAPTER 3</strong></td>
<td></td>
</tr>
<tr>
<td>3 Drug profile</td>
<td>49</td>
</tr>
<tr>
<td>3.1 Aliskiren hemifumarate</td>
<td>49</td>
</tr>
<tr>
<td>3.2 Amlodipine besilate</td>
<td>50</td>
</tr>
<tr>
<td>3.3 Hydrochlorothiazide</td>
<td>51</td>
</tr>
<tr>
<td>3.4 Valsartan</td>
<td>52</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHAPTER 4</td>
<td></td>
</tr>
<tr>
<td>4 Aim and objectives of the study</td>
<td>53</td>
</tr>
<tr>
<td>CHAPTER 5</td>
<td></td>
</tr>
<tr>
<td>5 Materials and methods</td>
<td>55</td>
</tr>
<tr>
<td>5.1 Materials</td>
<td>55</td>
</tr>
<tr>
<td>5.1.1 Pure drugs (reference substance)</td>
<td>55</td>
</tr>
<tr>
<td>5.1.1.1 Aliskiren hemifumarate</td>
<td>55</td>
</tr>
<tr>
<td>5.1.1.2 Amlodipine besilate</td>
<td>55</td>
</tr>
<tr>
<td>5.1.1.3 Hydrochlorothiazide</td>
<td>55</td>
</tr>
<tr>
<td>5.1.1.4 Valsartan</td>
<td>55</td>
</tr>
<tr>
<td>5.1.2 Marketed formulations (samples)</td>
<td>55</td>
</tr>
<tr>
<td>5.1.2.1 Formulation 1: Rasilez HCT tablet</td>
<td>55</td>
</tr>
<tr>
<td>5.1.2.2 Formulation 2: Valturna tablet</td>
<td>55</td>
</tr>
<tr>
<td>5.1.2.3 Formulation 3: Tekamlo tablet</td>
<td>55</td>
</tr>
<tr>
<td>5.1.2.4 Formulation 4: Amturnide tablet</td>
<td>55</td>
</tr>
<tr>
<td>5.1.3 Solvents &amp; chemicals</td>
<td>55</td>
</tr>
<tr>
<td>5.1.4 Instruments and equipments</td>
<td>56</td>
</tr>
<tr>
<td>5.1.4.1 UV-visible spectrophotometer</td>
<td>56</td>
</tr>
<tr>
<td>5.1.4.2 HPTLC</td>
<td>56</td>
</tr>
<tr>
<td>5.1.4.3 RP-HPLC</td>
<td>56</td>
</tr>
<tr>
<td>5.1.4.4 Digital balance</td>
<td>57</td>
</tr>
<tr>
<td>5.1.4.5 Water purifier (HPLC grade water)</td>
<td>57</td>
</tr>
<tr>
<td>5.1.4.6 Digital pH meter</td>
<td>57</td>
</tr>
<tr>
<td>5.1.4.7 Toshcon ultrasonic cleaner (sonicator)</td>
<td>57</td>
</tr>
<tr>
<td>5.2 Methods</td>
<td>58</td>
</tr>
<tr>
<td>Formulation 1</td>
<td>58</td>
</tr>
<tr>
<td>5.2.1 Method 1: Development and validation of simultaneous equation method for the simultaneous determination of <strong>aliskiren hemifumaramate</strong> and <strong>hydrochlorothiazide</strong> in tablet</td>
<td>58</td>
</tr>
<tr>
<td>5.2.1.1 Selection of solvent</td>
<td>58</td>
</tr>
<tr>
<td>5.2.1.2 Preparation of standard solution</td>
<td>58</td>
</tr>
<tr>
<td>5.2.1.3 Selection of wavelength</td>
<td>58</td>
</tr>
<tr>
<td>5.2.1.4 Determination of absorptivity value</td>
<td>58</td>
</tr>
<tr>
<td>5.2.1.5 Preparation of sample solution</td>
<td>59</td>
</tr>
<tr>
<td>5.2.1.6 Analysis of sample solution</td>
<td>59</td>
</tr>
<tr>
<td>5.2.1.7 Validation of the method</td>
<td>59</td>
</tr>
<tr>
<td>5.2.1.8 Specificity</td>
<td>59</td>
</tr>
<tr>
<td>5.2.1.9 Linearity and range</td>
<td>60</td>
</tr>
<tr>
<td>5.2.1.10 Precision</td>
<td>60</td>
</tr>
<tr>
<td>5.2.1.10.1 Repeatability of measurement</td>
<td>60</td>
</tr>
<tr>
<td>5.2.1.10.2 Intra-day precision</td>
<td>60</td>
</tr>
<tr>
<td>5.2.1.10.3 Inter-day precision</td>
<td>60</td>
</tr>
<tr>
<td>5.2.1.11 Accuracy</td>
<td>60</td>
</tr>
<tr>
<td>5.2.1.12 LOD and LOQ</td>
<td>61</td>
</tr>
<tr>
<td>5.2.1.13 Robustness</td>
<td>61</td>
</tr>
<tr>
<td>5.2.1.14 Stability of the solution</td>
<td>61</td>
</tr>
<tr>
<td>5.2.1.15 Analysis of marketed formulation using developed method</td>
<td>62</td>
</tr>
</tbody>
</table>
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>5.2.2</strong></td>
<td><strong>Method 2: Development and validation of absorbance ratio (Q analysis) method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets</strong></td>
</tr>
<tr>
<td>5.2.2.1</td>
<td>Selection of solvent</td>
</tr>
<tr>
<td>5.2.2.2</td>
<td>Preparation of standard solution</td>
</tr>
<tr>
<td>5.2.2.3</td>
<td>Selection of wavelength</td>
</tr>
<tr>
<td>5.2.2.4</td>
<td>Determination of absorptivity value</td>
</tr>
<tr>
<td>5.2.2.5</td>
<td>Preparation of sample solution</td>
</tr>
<tr>
<td>5.2.2.6</td>
<td>Analysis of sample solution</td>
</tr>
<tr>
<td>5.2.2.7</td>
<td>Validation of the method</td>
</tr>
<tr>
<td>5.2.2.8</td>
<td>Specificity</td>
</tr>
<tr>
<td>5.2.2.9</td>
<td>Linearity and range</td>
</tr>
<tr>
<td>5.2.2.10</td>
<td>Precision</td>
</tr>
<tr>
<td>5.2.2.10.1</td>
<td>Repeatability of measurement</td>
</tr>
<tr>
<td>5.2.2.10.2</td>
<td>Intra-day precision</td>
</tr>
<tr>
<td>5.2.2.10.3</td>
<td>Inter-day precision</td>
</tr>
<tr>
<td>5.2.2.11</td>
<td>Accuracy</td>
</tr>
<tr>
<td>5.2.2.12</td>
<td>LOD and LOQ</td>
</tr>
<tr>
<td>5.2.2.13</td>
<td>Robustness</td>
</tr>
<tr>
<td>5.2.2.14</td>
<td>Stability of the solution</td>
</tr>
<tr>
<td>5.2.2.15</td>
<td>Analysis of marketed formulation using developed method</td>
</tr>
<tr>
<td><strong>5.2.3</strong></td>
<td><strong>Method 3: Development and validation of first-derivative (zero crossing) spectroscopic method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets</strong></td>
</tr>
<tr>
<td>5.2.3.1</td>
<td>Selection of solvent</td>
</tr>
<tr>
<td>5.2.3.2</td>
<td>Preparation of standard solution</td>
</tr>
<tr>
<td>5.2.3.3</td>
<td>Selection of wavelength</td>
</tr>
<tr>
<td>5.2.3.4</td>
<td>Preparation of calibration curve</td>
</tr>
<tr>
<td>5.2.3.5</td>
<td>Preparation of sample solution</td>
</tr>
<tr>
<td>5.2.3.6</td>
<td>Analysis of sample solution</td>
</tr>
<tr>
<td>5.2.3.7</td>
<td>Validation of the method</td>
</tr>
<tr>
<td>5.2.3.8</td>
<td>Specificity</td>
</tr>
<tr>
<td>5.2.3.9</td>
<td>Linearity and range</td>
</tr>
<tr>
<td>5.2.3.10</td>
<td>Precision</td>
</tr>
<tr>
<td>5.2.3.10.1</td>
<td>Repeatability of measurement</td>
</tr>
<tr>
<td>5.2.3.10.2</td>
<td>Intra-day precision</td>
</tr>
<tr>
<td>5.2.3.10.3</td>
<td>Inter-day precision</td>
</tr>
<tr>
<td>5.2.3.11</td>
<td>Accuracy</td>
</tr>
<tr>
<td>5.2.3.12</td>
<td>LOD and LOQ</td>
</tr>
<tr>
<td>5.2.3.13</td>
<td>Robustness</td>
</tr>
<tr>
<td>5.2.3.14</td>
<td>Stability of the solution</td>
</tr>
<tr>
<td>5.2.3.15</td>
<td>Analysis of marketed formulation using developed method</td>
</tr>
<tr>
<td><strong>5.2.4</strong></td>
<td><strong>Method 4: Development and validation of RP-HPLC method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets</strong></td>
</tr>
<tr>
<td>5.2.4.1</td>
<td>Selection of mode of chromatographic method</td>
</tr>
<tr>
<td>5.2.4.2</td>
<td>Selection of column</td>
</tr>
<tr>
<td>Title</td>
<td>Page No.</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>5.2.4.3 Selection of wavelength</td>
<td>73</td>
</tr>
<tr>
<td>5.2.4.4 Trials for selection of mobile phase</td>
<td>73</td>
</tr>
<tr>
<td>5.2.4.5 Optimization of separation conditions</td>
<td>73</td>
</tr>
<tr>
<td>5.2.4.6 Preparation of standard solution</td>
<td>73</td>
</tr>
<tr>
<td>5.2.4.7 Preparation of sample solution</td>
<td>74</td>
</tr>
<tr>
<td>5.2.4.8 Validation of chromatographic method</td>
<td>74</td>
</tr>
<tr>
<td>5.2.4.9 Specificity</td>
<td>74</td>
</tr>
<tr>
<td>5.2.4.10 Linearity and range</td>
<td>74</td>
</tr>
<tr>
<td>5.2.4.11 Precision</td>
<td>74</td>
</tr>
<tr>
<td>5.2.4.11.1 Repeatability of measurement</td>
<td>75</td>
</tr>
<tr>
<td>5.2.4.11.2 Intra-day precision</td>
<td>75</td>
</tr>
<tr>
<td>5.2.4.11.3 Inter-day precision</td>
<td>75</td>
</tr>
<tr>
<td>5.2.4.12 Accuracy</td>
<td>75</td>
</tr>
<tr>
<td>5.2.4.13 LOD and LOQ</td>
<td>76</td>
</tr>
<tr>
<td>5.2.4.14 Robustness</td>
<td>76</td>
</tr>
<tr>
<td>5.2.4.15 Stability of the solution</td>
<td>76</td>
</tr>
<tr>
<td>5.2.4.16 System suitability test</td>
<td>76</td>
</tr>
<tr>
<td>5.2.4.17 Analysis of marketed formulation by developed method</td>
<td>76</td>
</tr>
<tr>
<td>Formulation 2</td>
<td></td>
</tr>
<tr>
<td>5.2.5 Method 5: Development and validation of simultaneous equation method for the simultaneous determination of aliskiren hemifumarate and valsartan in tablets</td>
<td>78</td>
</tr>
<tr>
<td>5.2.5.1 Selection of solvent</td>
<td>78</td>
</tr>
<tr>
<td>5.2.5.2 Preparation of standard solution</td>
<td>78</td>
</tr>
<tr>
<td>5.2.5.3 Selection of wavelength</td>
<td>78</td>
</tr>
<tr>
<td>5.2.5.4 Determination of absorptivity value</td>
<td>78</td>
</tr>
<tr>
<td>5.2.5.5 Preparation of sample solution</td>
<td>79</td>
</tr>
<tr>
<td>5.2.5.6 Analysis of sample solution</td>
<td>79</td>
</tr>
<tr>
<td>5.2.5.7 Validation of the method</td>
<td>79</td>
</tr>
<tr>
<td>5.2.5.8 Specificity</td>
<td>79</td>
</tr>
<tr>
<td>5.2.5.9 Linearity and range</td>
<td>80</td>
</tr>
<tr>
<td>3.2.5.10 Precision</td>
<td>80</td>
</tr>
<tr>
<td>3.2.5.10.1 Repeatability of measurement</td>
<td>80</td>
</tr>
<tr>
<td>5.2.5.10.2 Intra-day precision</td>
<td>80</td>
</tr>
<tr>
<td>5.2.5.10.3 Inter-day precision</td>
<td>80</td>
</tr>
<tr>
<td>5.2.5.11 Accuracy</td>
<td>81</td>
</tr>
<tr>
<td>5.2.5.12 LOD and LOQ</td>
<td>81</td>
</tr>
<tr>
<td>5.2.5.13 Robustness</td>
<td>81</td>
</tr>
<tr>
<td>5.2.5.14 Stability of the solution</td>
<td>82</td>
</tr>
<tr>
<td>5.2.5.15 Analysis of marketed formulation using developed method</td>
<td>82</td>
</tr>
<tr>
<td>5.2.6 Method 6: Development and validation of absorbance ratio (Q analysis) method for the simultaneous determination of aliskiren hemifumarate and valsartan in tablets</td>
<td>83</td>
</tr>
<tr>
<td>5.2.6.1 Selection of solvent</td>
<td>83</td>
</tr>
<tr>
<td>5.2.6.2 Preparation of standard solution</td>
<td>83</td>
</tr>
<tr>
<td>5.2.6.3 Selection of wavelength</td>
<td>83</td>
</tr>
<tr>
<td>5.2.6.4 Determination of absorptivity value</td>
<td>83</td>
</tr>
<tr>
<td>5.2.6.5 Preparation of sample solution</td>
<td>84</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2.6.6 Analysis of sample solution</td>
<td>84</td>
</tr>
<tr>
<td>5.2.6.7 Validation of the method</td>
<td>84</td>
</tr>
<tr>
<td>5.2.6.8 Specificity</td>
<td>84</td>
</tr>
<tr>
<td>5.2.6.9 Linearity and range</td>
<td>85</td>
</tr>
<tr>
<td>5.2.6.10 Precision</td>
<td>85</td>
</tr>
<tr>
<td>5.2.6.10.1 Repeatability of measurement</td>
<td>85</td>
</tr>
<tr>
<td>5.2.6.10.2 Intra-day precision</td>
<td>85</td>
</tr>
<tr>
<td>5.2.6.10.3 Inter-day precision</td>
<td>85</td>
</tr>
<tr>
<td>5.2.6.11 Accuracy</td>
<td>85</td>
</tr>
<tr>
<td>5.2.6.12 LOD and LOQ</td>
<td>86</td>
</tr>
<tr>
<td>5.2.6.13 Robustness</td>
<td>86</td>
</tr>
<tr>
<td>5.2.6.14 Stability of the solution</td>
<td>86</td>
</tr>
<tr>
<td>5.2.6.15 Analysis of marketed formulation using developed method</td>
<td>87</td>
</tr>
<tr>
<td>**5.2.7 Method 7: Development and validation of first-derivative</td>
<td>88</td>
</tr>
<tr>
<td>(zero crossing) spectroscopic method for the simultaneous</td>
<td></td>
</tr>
<tr>
<td>determination of aliskiren hemifumarate and valsartan in tablets</td>
<td></td>
</tr>
<tr>
<td>5.2.7.1 Selection of solvent</td>
<td>88</td>
</tr>
<tr>
<td>5.2.7.2 Preparation of standard solution</td>
<td>88</td>
</tr>
<tr>
<td>5.2.7.3 Selection of wavelength</td>
<td>89</td>
</tr>
<tr>
<td>5.2.7.4 Preparation of calibration curve</td>
<td>89</td>
</tr>
<tr>
<td>5.2.7.5 Preparation of sample solution</td>
<td>89</td>
</tr>
<tr>
<td>5.2.7.6 Analysis of sample solution</td>
<td>89</td>
</tr>
<tr>
<td>5.2.7.7 Validation of the method</td>
<td>90</td>
</tr>
<tr>
<td>5.2.7.8 Specificity</td>
<td>90</td>
</tr>
<tr>
<td>5.2.7.9 Linearity and range</td>
<td>90</td>
</tr>
<tr>
<td>5.2.7.10 Precision</td>
<td>90</td>
</tr>
<tr>
<td>5.2.7.10.1 Repeatability of measurement</td>
<td>90</td>
</tr>
<tr>
<td>5.2.7.10.2 Intra-day precision</td>
<td>90</td>
</tr>
<tr>
<td>5.2.7.10.3 Inter-day precision</td>
<td>91</td>
</tr>
<tr>
<td>5.2.7.11 Accuracy</td>
<td>91</td>
</tr>
<tr>
<td>5.2.7.12 LOD and LOQ</td>
<td>91</td>
</tr>
<tr>
<td>5.2.7.13 Robustness</td>
<td>91</td>
</tr>
<tr>
<td>5.2.7.14 Stability of the solution</td>
<td>92</td>
</tr>
<tr>
<td>5.2.7.15 Analysis of marketed formulation using developed method</td>
<td>92</td>
</tr>
<tr>
<td>**5.2.8 Method 8: Development and validation of RP-HPLC method</td>
<td>93</td>
</tr>
<tr>
<td>for the simultaneous determination of aliskiren hemifumarate and</td>
<td></td>
</tr>
<tr>
<td>valsartan in tablets</td>
<td></td>
</tr>
<tr>
<td>5.2.8.1 Selection of mode of chromatographic method</td>
<td>93</td>
</tr>
<tr>
<td>5.2.8.2 Selection of column</td>
<td>93</td>
</tr>
<tr>
<td>5.2.8.3 Selection of wavelength</td>
<td>93</td>
</tr>
<tr>
<td>5.2.8.4 Trials for selection of mobile phase</td>
<td>93</td>
</tr>
<tr>
<td>5.2.8.5 Optimization of separation conditions</td>
<td>93</td>
</tr>
<tr>
<td>5.2.8.6 Preparation of standard solution</td>
<td>93</td>
</tr>
<tr>
<td>5.2.8.7 Preparation of sample solution</td>
<td>94</td>
</tr>
<tr>
<td>5.2.8.8 Validation of chromatographic method</td>
<td>94</td>
</tr>
<tr>
<td>5.2.8.9 Specificity</td>
<td>94</td>
</tr>
<tr>
<td>5.2.8.10 Linearity and range</td>
<td>94</td>
</tr>
<tr>
<td>Title</td>
<td>Page No.</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
</tr>
<tr>
<td>5.2.8.11</td>
<td>Precision</td>
</tr>
<tr>
<td>5.2.8.11.1</td>
<td>Repeatability of measurement</td>
</tr>
<tr>
<td>5.2.8.11.2</td>
<td>Intra-day precision</td>
</tr>
<tr>
<td>5.2.8.11.3</td>
<td>Inter-day precision</td>
</tr>
<tr>
<td>5.2.8.12</td>
<td>Accuracy</td>
</tr>
<tr>
<td>5.2.8.13</td>
<td>LOD and LOQ</td>
</tr>
<tr>
<td>5.2.8.14</td>
<td>Robustness</td>
</tr>
<tr>
<td>5.2.8.15</td>
<td>Stability of the solution</td>
</tr>
<tr>
<td>5.2.8.16</td>
<td>System suitability test</td>
</tr>
<tr>
<td>5.2.8.17</td>
<td>Analysis of marketed formulation using developed method</td>
</tr>
</tbody>
</table>

**5.2.9 Method 9: Development and validation of HPTLC method for the simultaneous determination of aliskiren hemifumarate and valsartan in tablets**

- 5.2.9.1 Selection of mode of chromatographic method | 97 |
- 5.2.9.2 Selection of solvent | 97 |
- 5.2.9.3 Selection of wavelength | 97 |
- 5.2.9.4 Trials for selection of mobile phase | 97 |
- 5.2.9.5 Optimization of separation conditions | 97 |
- 5.2.9.6 Preparation of standard solution | 97 |
- 5.2.9.7 Preparation of sample solution | 98 |
- 5.2.9.8 Validation of chromatographic method | 98 |
- 5.2.9.9 Specificity | 98 |
- 5.2.9.10 Linearity and range | 98 |
- 5.2.9.11 Precision | 99 |
- 5.2.9.11.1 Repeatability of measurement | 99 |
- 5.2.9.11.2 Intra-day precision | 99 |
- 5.2.9.11.3 Inter-day precision | 99 |
- 5.2.9.12 Accuracy | 99 |
- 5.2.9.13 LOD and LOQ | 100 |
- 5.2.9.14 Robustness | 100 |
- 5.2.9.15 Stability of the solution | 100 |
- 5.2.9.16 Analysis of marketed formulation using developed method | 100 |

**Formulation 3**

**5.2.10 Method 10: Development and validation of simultaneous equation method for the simultaneous determination of aliskiren hemifumarate and amlodipine besilate in tablets**

- 5.2.10.1 Selection of solvent | 101 |
- 5.2.10.2 Preparation of standard solution | 101 |
- 5.2.10.3 Selection of wavelength | 101 |
- 5.2.10.4 Determination of absorptivity value | 101 |
- 5.2.10.5 Preparation of sample solution | 102 |
- 5.2.10.6 Analysis of sample solution | 102 |
- 5.2.10.7 Validation of the method | 102 |
- 5.2.10.8 Specificity | 103 |
- 5.2.10.9 Linearity and range | 103 |
- 5.2.10.10 Precision | 103 |
- 5.2.10.10.1 Repeatability of measurement | 103 |
- 5.2.10.10.2 Intra-day precision | 103 |
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2.10.3 Inter-day precision</td>
<td>103</td>
</tr>
<tr>
<td>5.2.10.11 Accuracy</td>
<td>104</td>
</tr>
<tr>
<td>5.2.10.11 LOD and LOQ</td>
<td>104</td>
</tr>
<tr>
<td>5.2.10.12 Robustness</td>
<td>104</td>
</tr>
<tr>
<td>5.2.10.13 Stability of the solution</td>
<td>105</td>
</tr>
<tr>
<td>5.2.10.14 Analysis of marketed formulation using developed method</td>
<td>105</td>
</tr>
<tr>
<td>**5.2.11 Method 11: Development and validation of absorbance ratio</td>
<td>106</td>
</tr>
<tr>
<td>(Q analysis) method for the simultaneous determination of aliskiren</td>
<td></td>
</tr>
<tr>
<td>hemifumarate and amlodipine besilate in tablets</td>
<td></td>
</tr>
<tr>
<td>5.2.11.1 Selection of solvent</td>
<td>106</td>
</tr>
<tr>
<td>5.2.11.2 Preparation of standard solution</td>
<td>106</td>
</tr>
<tr>
<td>5.2.11.3 Selection of wavelength</td>
<td>106</td>
</tr>
<tr>
<td>5.2.11.4 Determination of absorptivity value</td>
<td>106</td>
</tr>
<tr>
<td>5.2.11.5 Preparation of sample solution</td>
<td>107</td>
</tr>
<tr>
<td>5.2.11.6 Analysis of sample solution</td>
<td>107</td>
</tr>
<tr>
<td>5.2.11.7 Validation of the method</td>
<td>107</td>
</tr>
<tr>
<td>5.2.11.8 Specificity</td>
<td>108</td>
</tr>
<tr>
<td>5.2.11.9 Linearity and range</td>
<td>108</td>
</tr>
<tr>
<td>5.2.11.10 Precision</td>
<td>108</td>
</tr>
<tr>
<td>5.2.11.10.1 Repeatability of measurement</td>
<td>108</td>
</tr>
<tr>
<td>5.2.11.10.2 Intra-day precision</td>
<td>108</td>
</tr>
<tr>
<td>5.2.11.10.3 Inter-day precision</td>
<td>108</td>
</tr>
<tr>
<td>5.2.11.11 Accuracy</td>
<td>109</td>
</tr>
<tr>
<td>5.2.11.12 LOD and LOQ</td>
<td>109</td>
</tr>
<tr>
<td>5.2.11.13 Robustness</td>
<td>109</td>
</tr>
<tr>
<td>5.2.11.14 Stability of the solution</td>
<td>110</td>
</tr>
<tr>
<td>5.2.11.15 Analysis of marketed formulation using developed method</td>
<td>110</td>
</tr>
<tr>
<td>**5.2.12 Method 12: Development and validation of first-derivative</td>
<td>111</td>
</tr>
<tr>
<td>(zero crossing) spectroscopic method for the simultaneous determin</td>
<td></td>
</tr>
<tr>
<td>ation of aliskiren hemifumarate and amlodipine besilate in tablets</td>
<td></td>
</tr>
<tr>
<td>5.2.12.1 Selection of solvent</td>
<td>111</td>
</tr>
<tr>
<td>5.2.12.2 Preparation of standard solution</td>
<td>111</td>
</tr>
<tr>
<td>5.2.12.3 Selection of wavelength</td>
<td>112</td>
</tr>
<tr>
<td>5.2.12.4 Preparation of calibration curve</td>
<td>112</td>
</tr>
<tr>
<td>5.2.12.5 Preparation of sample solution</td>
<td>112</td>
</tr>
<tr>
<td>5.2.12.6 Analysis of sample solution</td>
<td>113</td>
</tr>
<tr>
<td>5.2.12.7 Validation of the method</td>
<td>113</td>
</tr>
<tr>
<td>5.2.12.8 Specificity</td>
<td>113</td>
</tr>
<tr>
<td>5.2.12.9 Linearity and range</td>
<td>113</td>
</tr>
<tr>
<td>5.2.12.10 Precision</td>
<td>113</td>
</tr>
<tr>
<td>5.2.12.10.1 Repeatability of measurement</td>
<td>113</td>
</tr>
<tr>
<td>5.2.12.10.2 Intra-day precision</td>
<td>114</td>
</tr>
<tr>
<td>5.2.12.10.3 Inter-day precision</td>
<td>114</td>
</tr>
<tr>
<td>5.2.12.11 Accuracy</td>
<td>114</td>
</tr>
<tr>
<td>5.2.12.12 LOD and LOQ</td>
<td>114</td>
</tr>
<tr>
<td>5.2.12.13 Robustness</td>
<td>115</td>
</tr>
<tr>
<td>5.2.12.14 Stability of the solution</td>
<td>115</td>
</tr>
</tbody>
</table>
CHAPTER 6

6 Results and discussion

6.1 Method 1: Development and validation of simultaneous equation method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets

6.2 Method 2: Development and validation of absorbance ratio (Q analysis) method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets

6.3 Method 3: Development and validation of first-derivative (zero crossing) spectroscopic method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets

6.4 Method 4: Development and validation of RP-HPLC method for the simultaneous determination of aliskiren hemifumarate and hydrochlorothiazide in tablets

6.5 Method 5: Development and validation of simultaneous equation method for the simultaneous determination of aliskiren hemifumarate and valsartan in tablets

6.6 Method 6: Development and validation of absorbance ratio (Q analysis) method for the simultaneous determination of aliskiren hemifumarate and valsartan in tablets

6.7 Method 7: Development and validation of first-derivative (zero crossing) spectroscopic method for the simultaneous determination of aliskiren
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>hemifumarate and valsartan in tablets</td>
<td></td>
</tr>
<tr>
<td>6.8 Method 8: Development and validation of RP-HPLC method for the</td>
<td>189</td>
</tr>
<tr>
<td>simultaneous determination of aliskiren hemifumarate and valsartan in</td>
<td></td>
</tr>
<tr>
<td>tablets</td>
<td></td>
</tr>
<tr>
<td>6.9 Method 9: Development and validation of HPTLC method for the</td>
<td>203</td>
</tr>
<tr>
<td>simultaneous determination of aliskiren hemifumarate and valsartan in</td>
<td></td>
</tr>
<tr>
<td>tablets</td>
<td></td>
</tr>
<tr>
<td>6.10 Method 10: Development and validation of simultaneous equation</td>
<td>218</td>
</tr>
<tr>
<td>method for the simultaneous determination of aliskiren hemifumarate</td>
<td></td>
</tr>
<tr>
<td>and valsartan in tablets</td>
<td></td>
</tr>
<tr>
<td>6.11 Method 11: Development and validation of absorbance ratio (Q</td>
<td>227</td>
</tr>
<tr>
<td>analysis) method for the simultaneous determination of aliskiren</td>
<td></td>
</tr>
<tr>
<td>hemifumarate and amlodipine besilate in tablets</td>
<td></td>
</tr>
<tr>
<td>6.12 Method 12: Development and validation of first-derivative (zero</td>
<td>236</td>
</tr>
<tr>
<td>crossing) spectroscopic method for the simultaneous determination of</td>
<td></td>
</tr>
<tr>
<td>aliskiren hemifumarate and amlodipine besilate in tablets</td>
<td></td>
</tr>
<tr>
<td>6.13 Method 13: Development and validation of RP-HPLC method for the</td>
<td>245</td>
</tr>
<tr>
<td>simultaneous determination of aliskiren hemifumarate, amlodipine</td>
<td></td>
</tr>
<tr>
<td>besilate and hydrochlorothiazide in tablets</td>
<td></td>
</tr>
<tr>
<td><strong>CHAPTER 7</strong></td>
<td></td>
</tr>
<tr>
<td>Conclusions</td>
<td>262</td>
</tr>
<tr>
<td><strong>CHAPTER 8</strong></td>
<td></td>
</tr>
<tr>
<td>References</td>
<td>263</td>
</tr>
<tr>
<td>Publication</td>
<td></td>
</tr>
</tbody>
</table>